Skip to main content

FDA Pulls Darvon & Darvocet Due to Cardiac Risk

The Food & Drug Administration (FDA) has issued an order to withdraw Darvon, Darvocet and generic versions of the drug propoxyphene due to risk of cardiac toxicity.

The FDA has concluded that the safety risks of propoxyphene outweigh its benefits for pain relief at recommended doses.

Click here to read a press release from the FDA on this withdrawal, including background information and recommendations. also has additional information.

Lynn Eschenbacher is clinical manager of the WakeMed Pharmacy.